Inhibrx, Inc.




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-23 pm EST 5-day change 1st Jan Change
38.28 USD -0.13% Intraday chart for Inhibrx, Inc. +1.59% +0.74%
This article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
North American Morning Briefing : S&P 500 Futures Point to Fresh Record on Netflix Results DJ
Health Care Flat After J&J Earnings -- Health Care Roundup DJ
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Sector Update: Health Care Stocks Decline Late Afternoon MT
Sector Update: Health Care MT
Sanofi Agrees to Buy Inhibrx' Rare Disease Candidate For Up To $2.2 Billion MT
CAC40: slight decline in the absence of catalysts CF
CAC40: down in the wake of Bunds and US T-Bonds CF
News Highlights : Top Company News of the Day - Tuesday at 11 AM ET DJ
CAC40: falls back below 7,400, Wall-Street reopens unchanged CF
News Highlights : Top Company News of the Day - Tuesday at 9 AM ET DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Earnings Peak MT
Sector Update: Health Care MT
JMP Securities Downgrades Inhibrx to Market Perform From Market Outperform MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update DJ
Sanofi to Acquire Inhibrx for Up to $2.2 Billion MT
European Midday Briefing : Caution Dominates as Focus Back on Big-Name U.S. Earnngs DJ
News Highlights : Top Company News of the Day - Tuesday at 5 AM ET DJ
CAC40: little movement, caution prevails CF
News Highlights : Top Company News of the Day - Tuesday at 3 AM ET DJ
Sanofi: agreement to acquire Inhibrx CF
Sanofi to Buy US-based Biopharmaceutical Group Inhibrx for $1.7 Billion MT
France's Sanofi to buy U.S. drugs project INBRX-101 for around $2.2 bln RE
Chart Inhibrx, Inc.
More charts
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of biologic therapeutic candidates in oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, INBRX-109, INBRX-105 and INBRX-106. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2. INBRX-105 is a conditional tetravelent PD-L1 targeted 4-1BB agonist that is being investigated as a single agent and in combination with Keytruda in patients with locally advanced or metastatic solid tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
38.28 USD
Average target price
35.5 USD
Spread / Average Target
1st Jan change Capi.
+0.74% 1 814 M $
+5.69% 111 B $
+11.72% 105 B $
+9.93% 24 182 M $
-10.96% 22 338 M $
-26.36% 21 352 M $
-6.59% 19 088 M $
-14.01% 16 173 M $
+1.84% 13 352 M $
+41.59% 12 772 M $
Bio Therapeutic Drugs
  1. Stock
  2. Equities
  3. Stock Inhibrx, Inc. - Nasdaq
  4. News Inhibrx, Inc.
  5. Arecor Therapeutics to Receive Milestone Payment from Inhibrx
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.